Major results of a phase III comparative multicenter study on the follitropin alfa biosimilar (Primapur®) and the original follitropin alfa (Gonal-f®)

• Autores principales: Z. B. Barakhoeva (Autor), L. A. Vovk (Autor), I. V. Zorina (Autor), N. Yu. Belousova (Autor), T. A. Teterina (Autor), S. A. Yakovenko (Autor), V. P. Apryshko (Autor), Yu. A. Fetisova (Autor), N. A. Marilova (Autor), E. G. Morozova (Autor), M. M. Ovchinnikova (Autor), M. A. Tishenko (Autor), Yu. V. Sherbatyuk (Autor), A. V. Kolotovkina (Autor), A. A. Miskun (Autor), G. V. Kasyanova (Autor), L. G. Sichinava (Autor), R. I. Shalinа (Autor), M. A. Polzikov (Autor)
• Formato: Libro
• Publicado: IRBIS LLC, 2018-11-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

A clinical study on the efficacy and safety of follitropin alfa has been conducted. The aim of the study was to confirm the therapeutic equivalence between the follitropin alfa biosimilar (Primapur®) and the reference medication (Gonal-f®) in controlled induction of superovulation within the assiste...